# data[].attributes.body
Do you think phages will one day play an important role in our life?

# data[].attributes.body
1. Enterobacteriaceae: Enterobacteriaceae is a family of bacteria that includes several genera, such as Escherichia coli and Klebsiella pneumoniae, which can cause a range of infections in humans.

2. Carbapenemase: Carbapenemases are enzymes produced by certain bacteria that can break down carbapenem antibiotics, which are often used as a last resort for treating bacterial infections. The presence of carbapenemases in bacteria can make them resistant to these antibiotics.

3. Antimicrobial stewardship: Antimicrobial stewardship refers to a set of strategies aimed at promoting the appropriate use of antibiotics and reducing the risk of antibiotic resistance. This can include efforts to optimize antibiotic prescribing, promote the use of narrow-spectrum antibiotics, and reduce unnecessary antibiotic use.

4. Multidrug-resistant: Multidrug-resistant refers to bacteria that are resistant to multiple antibiotics. These bacteria can pose a significant challenge for clinicians as they limit the available treatment options for infections caused by them.

5. Infection control: Infection control refers to a set of measures designed to prevent and control the spread of infectious diseases in healthcare settings. This can include practices such as hand hygiene, environmental cleaning, and isolation precautions for infected patients.

# data[].attributes.headline
The future of antibiotics: facing antibiotic resistance

# data[].attributes.subject
The future of antibiotics: facing antibiotic resistance

# data[].attributes.body
Some question:

1. How can improved infection control practices help prevent the spread of multiresitant becteria in healthcare settings?

2. What are some of the ethical considerations surrounding the use of experimental therapies to treat multiresitant becteria infections?

3. What are the potential long-term consequences of failing to control the spread of multiresitant becteria?

4. What research is needed to improve our understanding of multiresitant becteria and develop more effective strategies for controlling their spread?

# data[].attributes.body
1. convertible credit: A type of debt security that can be converted into equity or stock at a certain point in the future.

2. exquisitely: Extremely or intensely, often used to describe something that is very finely crafted or precise.

3. inherited: Passed down from one generation to another, often referring to genetic traits or characteristics.

4. adaptive: Able to change or adjust in response to new circumstances or challenges, often referring to evolutionary processes.

5. susceptibility: The state of being vulnerable or prone to a particular disease or condition, often referring to the susceptibility of a particular population or individual.

6. host specificity: The ability of a pathogen or parasite to infect only a particular host species or group of closely related species.

7. capsid: The protein shell that encloses the genetic material of a virus.

8. microbiome: The community of microorganisms (bacteria, fungi, viruses, etc.) that inhabit a particular environment or host organism.

9. antimicrobials: Agents (such as antibiotics, antivirals, or antifungals) that are used to treat or prevent infections caused by microorganisms.

10. cystic fibrosis: A genetic disorder that affects the lungs, pancreas, and other organs, characterized by the buildup of thick mucus and frequent respiratory infections.

# data[].attributes.attachment_link.readable_text
Ein Torte mit den Logos von PhagoMed und BionTech darauf - die Botschaft ist klar. Beim Wiener Biotech-Startup Phagomed wird derzeit gefeiert, und zwar die millionenschwere Übernahme durch den deutschen BioTech-Riesen BioNTech, der durch seinen Corona-Impfstoff Weltberühmtheit erlangte. Dem Handelsblatt zufolge hat der Mainzer Impfstoff-Experte für bis zu 150 Millionen Euro für die 2017 in Wien gegründete Firma bezahlt.

PhagoMed wurde auch bereits in BioNTech R&D (Austria) GmbH umbenannt, die Co-Founder Lorenzo Corsini und Alexander Belcredi sind weiter als Geschäftsführer für die Wiener Firma tätig. Sie konnte sich bereits einen Namen in der Branche machen, weil sie an einer Renaissance der Phagentherapie in der westlichen Medizin arbeiten. Phagen sind eine spezielle Klasse von Viren, die ausschließlich Bakterien befallen und diese töten können - und das macht sich PhagoMed bei neuen Medikamenten als Alternative zu herkömmlichen Antiobotika zunutze.

PhagoMed: 1,5 Millionen Euro für das Wiener Biotech, das Bakterien killen will

„Neue Klasse von Antibiotika"

„Im Oktober 2021 erweiterte BioNTech sein Portfolio für Infektionskrankheiten durch die Übernahme der PhagoMed Biopharma GmbH, einem österreichischen Biotechnologieunternehmen, das auf die Entwicklung einer neuen Klasse von Antibiotika spezialisiert ist", heißt es in einer knappen Mitteilung der Mainzer an die Investoren.

Nun soll das passieren, was meistens passiert, wenn eine große Übernahme erfolgt und viel Geld fließt: Es werden viele neue Jobs am Standort Wien geschaffen. BioNTech hat natürlich das nötige Kapital, um so große Übernahmen zu machen. Der Corona-Impfstoff, weltweit in Zusammenarbeit mit Pfizer im Einsatz, bringt dem Mainzer Unternehmen Umsatz in den ersten neun Monaten des Jahres satte 13,4 Milliarden Euro Umsatz - bei einem Vorsteuergewinn von 10,3 Milliarden Euro. Die etwa 150 Millionen Euro, die BioNTech für die Wiener zahlte, sind also eher Kleingeld.

PhagoMed hatte zuvor Investoren wie Business Angels und Family Offices an Bord und hat sich außerdem Förderungen bei der FFG und aws geholt. Neben einigen anderen Biotechs ist die 2017 gegründete Firma ein weiteres Beispiel für einen großen Erfolg aus dem österreichischen Standort heraus.

BioNTech: So funktioniert der Covid-19-Impfstoff

# data[].attributes.attachment_link.title
Wiener Biotech Phagomed wird von Impfstoffriesen BioNTech geschluckt

# data[].attributes.attachment_link.description
Ein Torte mit den Logos von PhagoMed und BionTech darauf - die Botschaft ist klar. Beim Wiener Biotech-Startup Phagomed wird derzeit gefeiert, und zwar die millionenschwere Übernahme durch den deutschen BioTech-Riesen BioNTech, der durch seinen Corona-Impfstoff Weltberühmtheit erlangte. Dem Handelsblatt zufolge hat der Mainzer Impfstoff-Experte für bis zu 150 Millionen Euro für die 2017 in Wien gegründete Firma bezahlt.

# data[].attributes.headline
WHO Report on the future of antibiotic resistent bacteria

# data[].attributes.subject
WHO Report on the future of antibiotic resistent bacteria

# data[].attributes.attachment_link.description
Fact sheet: Antibiotics are medicines used to prevent and treat bacterial infections. Antibiotic resistance occurs when bacteria change in response to the use of these medicines. Bacteria, not humans, become antibiotic resistant. These bacteria may then infect humans and are harder to treat than non…

# data[].attributes.body
Discuss 5 groups:

1. Do you know other areas where phages could be useful?

2. Why is it important to preserve it when developing new antimicrobials?

3. Do you know other biotech-companies and if so, what product do they develop?

4. What are some challenges that need to be overcome in the development and regulation of phage-based therapies, and how might these challenges be addressed?

5. What are some potential applications of phage technology beyond antimicrobial therapy, and how might these applications impact fields like biotechnology, environmental science, or molecular biology?

# data[].attributes.attachment_link.title
Microbiome-friendly phages join the campaign for better antimicrobials

# data[].attributes.headline
Ways to combat antimicrobial resistenses  bacteria

# data[].attributes.subject
Ways to combat antimicrobial resistenses  bacteria

# data[].attributes.attachment_link.title
new weapons to combat antibiotic resistance-ZZAD18003ENN (1)

# data[].attributes.body
Phages (short for bacteriophages) are viruses that infect bacteria. They have a unique structure and several properties that distinguish them from other viruses. Here are some key features of phages:

1. Structure: Phages consist of a protein capsid that encloses their genetic material, which can be either DNA or RNA. Some phages also have an envelope or an outer membrane made up of lipids that surround their capsid. The shape of the capsid can be either icosahedral or filamentous.

2. Host specificity: Phages are highly specific in their choice of host bacteria. Each phage can infect only a limited range of bacterial species or strains. This specificity is due to the recognition of specific receptors on the bacterial surface by the phage.

3. Lytic and lysogenic cycles: Phages can undergo two different life cycles upon infection of a host bacterium. The lytic cycle results in the destruction of the host cell and release of new phages, while the lysogenic cycle results in the integration of the phage DNA into the host chromosome, forming a prophage that replicates along with the host DNA.

4. Rapid replication: Phages can replicate very quickly within a host bacterium, with a single infected cell producing thousands of new phages in just a few hours.

5. Genetic diversity: Phages are the most diverse biological entities on Earth, with an estimated 10^31 different phages in the biosphere. This diversity is due to the high mutation rate and recombination of phage genomes, as well as the rapid evolution driven by host bacteria.

6. Potential therapeutic applications: Because of their specificity and ability to rapidly replicate within bacterial cells, phages have been proposed as potential alternatives to antibiotics for the treatment of bacterial infections.

# data[].attributes.body
1. Improved infection control practices, such as hand hygiene and disinfection protocols, can reduce the transmission of CRE between patients and healthcare workers, and limit the development of antibiotic resistance.

2. The use of experimental therapies to treat CRE infections raises concerns about safety, efficacy, and access.

3. Failing to control the spread of CRE can lead to increased morbidity, mortality, and healthcare costs due to the development of antibiotic resistance.

4. Research is needed to improve our understanding of the genetics and mechanisms of antibiotic resistance in CRE, as well as to investigate new diagnostic methods, therapies, and infection control practices. Additionally, more research is needed to develop ethical guidelines for the use of experimental therapies.